Medical Devices

A new toothbrush using safe microcurrents claims to remove 6x more plaque and cut gum inflammation. Does the science behind this oral care revolution hold up?

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.

Establishment Labs has submitted its innovative Motiva implants for FDA approval in reconstruction, promising a new era for post-mastectomy care.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

Diamyd Medical's pivotal Phase 3 trial gets a nine-month acceleration, raising hopes for a new precision therapy that preserves insulin production.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

A new cell-free therapy for the fatal lung disease IPF is heading to clinical trials, thanks to a key manufacturing partnership. Here's what it means.

Swisslog Healthcare appoints Maria Garces from competitor Omnicell as VP, signaling an aggressive push to innovate and dominate the health tech market.

A new class action lawsuit accuses medical device firm Integer Holdings of hiding poor sales while touting growth, leading to a major stock drop.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

A landmark executive order reclassifying cannabis is set to unleash a wave of biopharma innovation, validating science-first firms like Avicanna.

A strategic partnership aims to merge respiratory rentals with innovative hygiene products, promising better compliance and comfort for millions of CPAP users.

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

Researchers at Kanazawa University have developed engineered nanoparticles that can reprogram rogue immune cells, offering a targeted therapy for autoimmune diseases.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

A new standing wheelchair module offers unprecedented height, blending advanced engineering with profound health and social benefits for users.

As pharma sells GLP-1s directly to patients, doctors are split on the new model. Is it a lifeline for access or a risk to integrated patient care?

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.